CYP4B1 is a prognostic biomarker and potential therapeutic target in lung adenocarcinoma

Autor: Yuanming Wu, Tiantian Zhang, Dechen Kong, Yichen Jia, Anjie Wei, Changyuan Shi, Dan Wang, Xiaoling Liu
Rok vydání: 2021
Předmět:
Male
Carcinogenesis
Cancer Treatment
medicine.disease_cause
Biochemistry
Lung and Intrathoracic Tumors
Medicine and Health Sciences
Molecular Targeted Therapy
Regulation of gene expression
DNA methylation
Multidisciplinary
Adenocarcinoma of the Lung
Middle Aged
Cell cycle
Prognosis
Chromatin
Gene Expression Regulation
Neoplastic
Nucleic acids
Oncology
Medicine
Adenocarcinoma
Female
Epigenetics
Aryl Hydrocarbon Hydroxylases
Metabolic Pathways
KRAS
DNA modification
Chromatin modification
Research Article
Chromosome biology
Clinical Oncology
Cell biology
Science
Radiation Therapy
Adenocarcinoma of Lung
Biomarkers
Tumor
Genetics
medicine
Humans
Xenobiotic Metabolism
Survival analysis
Aged
Biology and life sciences
Oncogene
business.industry
Carcinoma
Cancers and Neoplasms
DNA
medicine.disease
Metabolism
Cancer research
Gene expression
Clinical Medicine
business
Zdroj: PLoS ONE
PLoS ONE, Vol 16, Iss 2, p e0247020 (2021)
ISSN: 1932-6203
2344-0155
DOI: 10.1371/journal.pone.0247020
Popis: CYP4B1 belongs to the mammalian CYP4 enzyme family and is predominantly expressed in the lungs of humans. It is responsible for the oxidative metabolism of a wide range of endogenous compounds and xenobiotics. In this study, using data from The Cancer Genome Atlas (TCGA) project and the Gene Expression Omnibus (GEO) database, a secondary analysis was performed to explore the expression profile of CYP4B1, as well as its prognostic value in patients with lung adenocarcinoma (LUAD). Based on the obtained results, a significantly decreased CYP4B1 expression was discovered in patients with LUAD when compared with their normal counterparts (pp = 0.0041), history of pharmaceutical (p = 0.0127) and radiation (p = 0.0340) therapy, mutations in KRAS/EGFR/ALK (p = 0.0239), and living status of dead (p = 0.0026). Survival analysis indicated that the low CYP4B1 expression was an independent prognostic indicator of shorter survival in terms of overall survival (OS) and recurrence-free survival (RFS) in patients with LUAD. The copy number alterations (CNAs) and sites of cg23440155 and cg23414387 hypermethylation might contribute to the decreased CYP4B1 expression. Gene set enrichment analysis (GSEA) suggested that CYP4B1 might act as an oncogene in LUAD by preventing biological metabolism pathways of exogenous and endogenous compounds and enhancing DNA replication and cell cycle activities. In conclusion, CYP4B1 expression may serve as a valuable independent prognostic biomarker and a potential therapeutic target in patients with LUAD.
Databáze: OpenAIRE
Externí odkaz: